Search / Trial NCT06612593

Cilostazol in Parkinson's Disease

Launched by AIN SHAMS UNIVERSITY · Sep 22, 2024

Trial Information

Current as of December 30, 2024

Not yet recruiting

Keywords

Pd, Parkinson's Disease, Cilostazol, Neuroinflammation, Oxidative Stress, Anti Inflammatory, Anti Oxidant, Neuroprotective, Mds Updrs

ClinConnect Summary

Parkinson's disease (PD) is the second most common neurodegenerative disease, affecting about 1% of the elderly population, with 5 to over 35 new cases in 100,000 per year diagnosed with PD, with a prevalence of over 10 million people worldwide. This number is projected to increase to more than 12 million by 2040. The incidence of PD increase with age but it can affect people less than 50 years old. In the Eastern Mediterranean Region (EMR), the prevalence rate of PD increased by 42.3% over the period 1990-2016, and reached 87.1 per 100,000 in 2016. Factors that cause PD are multifactorial ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • -Adult patients.
  • Both males and females will be included
  • Diagnosed Parkinson's disease according to the MDS criteria 2015
  • At least 5 years of disease duration
  • On stable Levodopa\\carbidopa regimen for the past 6 months.
  • Clinically diagnosed with dyskinesia
  • Exclusion Criteria:
  • -Secondary causes of Parkinsonism
  • Atypical parkinsonian syndromes
  • Active malignancy
  • Known intolerance or hypersensitivity to cilostazol
  • Participation in other interventional trials
  • Patients with hepatic (AST and ALT more than 3 times the upper normal limit) or renal impairment (eGFR less than 60 ml\\min).
  • Patients receiving warfarin, other anti-coagulants or anti-platelet therapy.
  • Patients with Congestive heart failure.

About Ain Shams University

Ain Shams University, established in Cairo, Egypt, is a prestigious higher education institution renowned for its commitment to academic excellence and research innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise in various medical and scientific disciplines to advance healthcare through rigorous research initiatives. With a focus on ethical practices and adherence to regulatory standards, Ain Shams University aims to contribute to the development of new therapies and improve patient outcomes, fostering collaboration among researchers, healthcare professionals, and industry partners in the pursuit of medical advancements.

Locations

Cairo, , Egypt

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0